Hansa Biopharma treats first commercial Australian kidney transplant patient with Idefirix

PUBT · 1d ago
Hansa Biopharma treats first commercial Australian kidney transplant patient with Idefirix
  • Hansa Biopharma reported the first commercial Australian patient received Idefirix before a kidney transplant from a living donor.
  • No clinical results were presented; real-world outcomes will be collected in an Australian registry for potential future scientific publications.
  • Use supports rollout in a market where Idefirix is cleared for desensitization in highly sensitized adult candidates with a positive crossmatch.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202608180200BITN____UKPR__SV_20260818-BIT-8785-0) on August 18, 2026, and is solely responsible for the information contained therein.